DARE News and Press, Dare Bioscience Inc.

2024-07-19 08:14:49 ET More on Dare Bioscience Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript Brookline Capital upgrades Dare Bioscience, cites improved funding Dare Bioscience GAAP EPS of -$0.07 Seeking Alpha’s Quant Rating on Dare...

2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com

2024-06-27 08:28:44 ET More on Dare Bioscience Brookline Capital upgrades Dare Bioscience, cites improved funding Dare Bioscience GAAP EPS of -$0.07 Read the full article on Seeking Alpha For further details see: Daré Bioscience announces reverse sto...

Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...

Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...

2024-05-15 13:54:48 ET More on Dare Bioscience Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript Dare Bioscience GAAP EPS of -$0.07 Daré Bioscience secures $22 million in...

2024-05-14 18:30:25 ET Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript May 14, 2024 04:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO MarDee Haring-Layton - Chief Accounting Officer Conference Call Participants ...

2024-05-14 16:02:26 ET More on Dare Bioscience Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript Dare Bioscience GAAP EPS of -$0.07 Daré Bioscience secures $22 million in non-dilutive strategic royalty financing Seeking Alpha’s Qu...

2024-05-14 10:30:10 ET More on Dare Bioscience Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript Daré Bioscience secures $22 million in non-dilutive strategic royalty financing Dare Bioscience FY 2023 Earnings Preview Seeking Alphaȁ...

Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States Sildenafil Cream, 3.6% topical formulation of sildenafil b...